Table Info

Table 1.

Studies reporting changes in the human ocular surface microbiome of DED state subtypes compared to healthy controls

First author	Year	Study type	DED type	Patients (N)	Significant alpha diversity change	Increased bacterial abundance or detection	Decreased bacterial abundance or detection
Andersson [22]	2021	Case-control	ADDE	18	Reduced	NR	52 genera less abundant
Zhang [32]	2021	Case-control	NR	34	Not significant	Pseudomonas Methylobacterium Bacteroides	Actinobacteria
Zilliox [33]	2020	Case-control	NR	8	Reduced	Corynebacterium Staphylococcus	NR
Li [34]	2019	Case-control	Combined	35	Reduced	Bacteroidia Bacteroidetes	Pseudomonas Pseudomonas plecoglossicida Pseudomonadaceae Gammaproteobacteria Proteobacteria
Dong [21]	2019	Case-control	Evaporative	47	Not significant	Bacillales Proteobacteria Bacilli Staphylococcus Staphylococcaceae Firmicutes Staphlococcus epidermidis Alphaproteobacteria Gammaproteobacteria Sphingomonas Sphingomonadaceae Sphingomonadales Sphingomonas melonis	Actinomycetales Actinobacteria Corynebacteriaceae Corynebacterium
Jiang [26]	2018	Case-control	EDE	41	Increased	Bacillus Micrococcus luteus Staphylococcus epidermidis Staphylococcus Microbacteriaceae	NR
Graham [25]	2007	Case-control	NR	12	NR	Bacillus Propionbacterium acnes Klebsiella oxytoca	Erwinia

Studies restricted to those employing RNA or DNA sequencing in lieu of culture only. EDE: evaporative dry eye; NR: not recorded

Declarations

Author contributions

MP and BG: Writing—original draft, Writing—review & editing. DL and SLW: Writing—review & editing. KGJO: Conceptualization, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Smith JA. The epidemiology of dry eye disease. Acta Ophthalmol Scand. 2007;85. [DOI]

Zeev MS, Miller DD, Latkany R. Diagnosis of dry eye disease and emerging technologies. Clin Ophthalmol. 2014;8:581–90. [DOI] [PubMed] [PMC]

Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83. [DOI] [PubMed]

Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30:379–87. [DOI] [PubMed]

Farid M. Dry eye disease: Let’s start thinking outside of the artificial tear box. Ophthalmology. 2017;124:S1–3. [DOI] [PubMed]

Guo B, Gopinath B, Watson S, Burlutsky G, Mitchell P, Ooi K. Associations between intake of dietary micro- and macro-nutrients with dry eye syndrome: Blue Mountains Eye Study. Clin Nutr ESPEN. 2023;54:258–63. [DOI] [PubMed]

Molina-Leyva I, Molina-Leyva A, Riquelme-Gallego B, Cano-Ibáñez N, García-Molina L, Bueno-Cavanillas A. Effectiveness of Mediterranean diet implementation in dry eye parameters: a study of PREDIMED-PLUS trial. Nutrients. 2020;12:1289. [DOI] [PubMed] [PMC]

Bhargava R, Kumar P, Kumar M, Mehra N, Mishra A. A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol. 2013;6:811–6. [DOI] [PubMed] [PMC]

Kawakita T, Kawabata F, Tsuji T, Kawashima M, Shimmura S, Tsubota K. Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial. Biomed Res. 2013;34:215–20. [DOI] [PubMed]

10.

Kawashima M, Nakamura S, Izuta Y, Inoue S, Tsubota K. Dietary supplementation with a combination of lactoferrin, fish oil, and Enterococcus faecium WB2000 for treating dry eye: a rat model and human clinical study. Ocul Surf. 2016;14:255–63. [DOI] [PubMed]

11.

Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15:73. [DOI] [PubMed] [PMC]

12.

Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–12. [DOI] [PubMed] [PMC]

13.

Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–8. [DOI] [PubMed]

14.

Findlay Q, Reid K. Dry eye disease: when to treat and when to refer. Aust Prescr. 2018;41:160–3. [DOI] [PubMed] [PMC]

15.

Lemp MA, Foulks GN. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75–92. [DOI] [PubMed]

16.

Akpek EK, Bunya VY, Saldanha IJ. Sjögren’s syndrome: more than just dry eye. Cornea. 2019;38:658–61. [DOI] [PubMed] [PMC]

17.

Chiang MC, Chern E. Ocular surface microbiota: ophthalmic infectious disease and probiotics. Front Microbiol. 2022;13:952473. [DOI] [PubMed] [PMC]

18.

Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, et al. The conjunctival microbiome in health and trachomatous disease: a case control study. Genome Med. 2014;6:99. [DOI] [PubMed] [PMC]

19.

Doan T, Akileswaran L, Andersen D, Johnson B, Ko N, Shrestha A, et al. Paucibacterial microbiome and resident DNA virome of the healthy conjunctiva. Invest Ophthalmol Vis Sci. 2016;57:5116–26. [DOI] [PubMed] [PMC]

20.

Aragona P, Baudouin C, Benitez Del Castillo JM, Messmer E, Barabino S, Merayo-Lloves J, et al. The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. Surv Ophthalmol. 2021;66:907–25. [DOI] [PubMed]

21.

Dong X, Wang Y, Wang W, Lin P, Huang Y. Composition and diversity of bacterial community on the ocular surface of patients with meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2019;60:4774–83. [DOI] [PubMed]

22.

Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K, Heegaard S. Ocular surface microbiota in patients with aqueous tear-deficient dry eye. Ocul Surf. 2021;19:210–7. [DOI] [PubMed]

23.

de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep. 2016;6:23561. [DOI] [PubMed] [PMC]

24.

Terry MA. Dry eye in the elderly. Drugs Aging. 2001;18:101–7. [DOI] [PubMed]

25.

Graham JE, Moore JE, Jiru X, Moore JE, Goodall EA, Dooley JS, et al. Ocular pathogen or commensal: a PCR-based study of surface bacterial flora in normal and dry eyes. Invest Ophthalmol Vis Sci. 2007;48:5616–23. [DOI] [PubMed]

26.

Jiang X, Deng A, Yang J, Bai H, Yang Z, Wu J, et al. Pathogens in the Meibomian gland and conjunctival sac: microbiome of normal subjects and patients with Meibomian gland dysfunction. Infect Drug Resist. 2018;11:1729–40. [DOI] [PubMed] [PMC]

27.

Zhang SD, He JN, Niu TT, Chan CY, Ren CY, Liu SS, et al. Bacteriological profile of ocular surface flora in meibomian gland dysfunction. Ocul Surf. 2017;15:242–7. [DOI] [PubMed]

28.

Bernardes TF, Bonfioli AA. Blepharitis. Semin Ophthalmol. 2010;25:79–83. [DOI] [PubMed]

29.

Perkins RE, Kundsin RB, Pratt MV, Abrahamsen I, Leibowitz HM. Bacteriology of normal and infected conjunctiva. J Clin Microbiol. 1975;1:147–9. [DOI] [PubMed] [PMC]

30.

Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27:486–91. [PubMed]

31.

Lee SH, Oh DH, Jung JY, Kim JC, Jeon CO. Comparative ocular microbial communities in humans with and without blepharitis. Invest Ophthalmol Vis Sci. 2012;53:5585–93. [DOI] [PubMed]

32.

Zhang Z, Zou X, Xue W, Zhang P, Wang S, Zou H. Ocular surface microbiota in diabetic patients with dry eye disease. Invest Ophthalmol Vis Sci. 2021;62:13. [DOI] [PubMed] [PMC]

33.

Zilliox MJ, Gange WS, Kuffel G, Mores CR, Joyce C, de Bustros P, et al. Assessing the ocular surface microbiome in severe ocular surface diseases. Ocul Surf. 2020;18:706–12. [DOI] [PubMed] [PMC]

34.

Li Z, Gong Y, Chen S, Li S, Zhang Y, Zhong H, et al. Comparative portrayal of ocular surface microbe with and without dry eye. J Microbiol. 2019;57:1025–32. [DOI] [PubMed]

35.

Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12:1279–89. [DOI] [PubMed]

36.

Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. J Ophthalmol. 2012;2012:285851. [DOI] [PubMed] [PMC]

37.

Zhang R, Park M, Richardson A, Tedla N, Pandzic E, de Paiva CS, et al. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul Surf. 2020;18:158–69. [DOI] [PubMed]

38.

Chang CJ, Somohano K, Zemsky C, Uhlemann AC, Liebmann J, Cioffi GA, et al. Topical glaucoma therapy is associated with alterations of the ocular surface microbiome. Invest Ophthalmol Vis Sci. 2022;63:32. [DOI] [PubMed] [PMC]

39.

Floyd JL, Grant MB. The gut–eye axis: lessons learned from murine models. Ophthalmol Ther. 2020;9:499–513. [DOI] [PubMed] [PMC]

40.

Wang J, Chen WD, Wang YD. The relationship between gut microbiota and inflammatory diseases: the role of macrophages. Front Microbiol. 2020;11:1065. [DOI] [PubMed] [PMC]

41.

Rojas-Carabali W, Mejía-Salgado G, Cifuentes-González C, Villabona-Martínez V, Barraquer-López ND, Valdés-Arias D, et al. Clinical relationship between dry eye disease and uveitis: a scoping review. J Ophthalmic Inflamm Infect. 2023;13:2. [DOI] [PubMed] [PMC]

42.

Turner JR, McGwin G, Read RW. Episcleritis: association with dry eye disease. Invest Ophthalmol Vis Sci. 2010;51:6252.

43.

Moon J, Choi SH, Yoon CH, Kim MK. Gut dysbiosis is prevailing in Sjögren’s syndrome and is related to dry eye severity. PLoS One. 2020;15:e0229029. [DOI] [PubMed] [PMC]

44.

Huang X, Ye Z, Cao Q, Su G, Wang Q, Deng J, et al. Gut microbiota composition and fecal metabolic phenotype in patients with acute anterior uveitis. Invest Ophthalmol Vis Sci. 2018;59:1523–31. [DOI] [PubMed]

45.

Huang Y, Wang Z, Ma H, Ji S, Chen Z, Cui Z, et al. Dysbiosis and implication of the gut microbiota in diabetic retinopathy. Front Cell Infect Microbiol. 2021;11:646348. [DOI] [PubMed] [PMC]

46.

Li M, Yang L, Cao J, Liu T, Liu X. Enriched and decreased intestinal microbes in active VKH patients. Invest Ophthalmol Vis Sci. 2022;63:21. [DOI] [PubMed] [PMC]

47.

Wang Q, Wu S, Ye X, Tan S, Huang F, Su G, et al. Gut microbial signatures and their functions in Behcet’s uveitis and Vogt-Koyanagi-Harada disease. J Autoimmun. 2023;137:103055. [DOI] [PubMed]

48.

Su X, Yin X, Liu Y, Yan X, Zhang S, Wang X, et al. Gut dysbiosis contributes to the imbalance of Treg and Th17 cells in Graves’ disease patients by propionic acid. J Clin Endocrinol Metab. 2020;105:3526–47. [DOI] [PubMed]

49.

Shivaji S. A systematic review of gut microbiome and ocular inflammatory diseases: Are they associated? Indian J Ophthalmol. 2021;69:535–42. [DOI] [PubMed] [PMC]

50.

Yoon CH, Ryu JS, Moon J, Kim MK. Association between aging-dependent gut microbiome dysbiosis and dry eye severity in C57BL/6 male mouse model: a pilot study. BMC Microbiol. 2021;21:106. [DOI] [PubMed] [PMC]

51.

Zysset-Burri DC, Morandi S, Herzog EL, Berger LE, Zinkernagel MS. The role of the gut microbiome in eye diseases. Prog Retin Eye Res. 2023;92:101117. [DOI] [PubMed]

52.

Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014;19:164–74. [PubMed] [PMC]

53.

Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25:888–95. [DOI] [PubMed]

54.

Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22. [DOI] [PubMed] [PMC]

55.

Dostal A, Lacroix C, Bircher L, Pham VT, Follador R, Zimmermann MB, et al. Iron modulates butyrate production by a child gut microbiota in vitro. mBio. 2015;6:e01453–15. [DOI] [PubMed] [PMC]

56.

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104–19. [DOI] [PubMed]

57.

Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: a double-edged sword for health? Adv Nutr. 2018;9:21–9. [DOI] [PubMed] [PMC]

58.

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. Chapter three - the role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119. [DOI] [PubMed]

59.

Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease. Cells. 2021;10:1775. [DOI] [PubMed] [PMC]

60.

Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn’s disease. Gut. 2000;47:397–403. [DOI] [PubMed] [PMC]

61.

Biswas R, Bagchi A. NFkB pathway and inhibition: an overview. Comput Mol Biol. 2016;6:1–20. [DOI]

62.

Chriett S, Dąbek A, Wojtala M, Vidal H, Balcerczyk A, Pirola L. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci Rep. 2019;9:742. [DOI] [PubMed] [PMC]

63.

Schaefer L, Hernandez H, Coats RA, Yu Z, Pflugfelder SC, Britton RA, et al. Gut-derived butyrate suppresses ocular surface inflammation. Sci Rep. 2022;12:4512. [DOI] [PubMed] [PMC]

64.

Wang C, Schaefer L, Bian F, Yu Z, Pflugfelder SC, Britton RA, et al. Dysbiosis modulates ocular surface inflammatory response to liposaccharide. Invest Ophthalmol Vis Sci. 2019;60:4224–33. [DOI] [PubMed] [PMC]

65.

Bian F, Xiao Y, Zaheer M, Volpe EA, Pflugfelder SC, Li DQ, et al. Inhibition of NLRP3 inflammasome pathway by butyrate improves corneal wound healing in corneal alkali burn. Int J Mol Sci. 2017;18:562. [DOI] [PubMed] [PMC]

66.

Shimizu H, Sakimoto T, Yamagami S. Pro-inflammatory role of NLRP3 inflammasome in experimental sterile corneal inflammation. Sci Rep. 2019;9:9596. [DOI] [PubMed] [PMC]

67.

Lurz E, Horne RG, Määttänen P, Wu RY, Botts SR, Li B, et al. Vitamin B12 deficiency alters the gut microbiota in a murine model of colitis. Front Nutr. 2020;7:83. [DOI] [PubMed] [PMC]

68.

Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7:235–41. [PubMed] [PMC]

69.

Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9. [DOI] [PubMed]

70.

Degnan PH, Taga ME, Goodman AL. Vitamin B₁₂as a modulator of gut microbial ecology. Cell Metab. 2014;20:769–78. [DOI] [PubMed] [PMC]

71.

Wan Z, Zheng J, Zhu Z, Sang L, Zhu J, Luo S, et al. Intermediate role of gut microbiota in vitamin B nutrition and its influences on human health. Front Nutr. 2022;9:1031502. [DOI] [PubMed] [PMC]

72.

Hossain KS, Amarasena S, Mayengbam S. B vitamins and their roles in gut health. Microorganisms. 2022;10:1168. [DOI] [PubMed] [PMC]

73.

Forgie AJ, Pepin DM, Ju T, Tollenaar S, Sergi CM, Gruenheid S, et al. Over supplementation with vitamin B12 alters microbe-host interactions in the gut leading to accelerated Citrobacter rodentium colonization and pathogenesis in mice. Microbiome. 2023;11:21. [DOI] [PubMed] [PMC]

74.

Ozen S, Ozer MA, Akdemir MO. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain. Graefes Arch Clin Exp Ophthalmol. 2017;255:1173–7. [DOI] [PubMed]

75.

Yang J, Liu Y, Xu Y, Li X, Fu J, Jiang X, et al. A new approach of ocular nebulization with vitamin B12 versus oxytocin for the treatment of dry eye disease: an in vivo confocal microscopy study. Drug Des Devel Ther. 2019;13:2381–91. [DOI] [PubMed] [PMC]

76.

Seen S, Tong L. Dry eye disease and oxidative stress. Acta Ophthalmol. 2018;96:e412–20. [DOI] [PubMed]

77.

van de Lagemaat EE, de Groot LCPGM, van den Heuvel EGHM. Vitamin B₁₂in relation to oxidative stress: a systematic review. Nutrients. 2019;11:482. [DOI] [PubMed] [PMC]

78.

Sun H, Yang T, Li Q, Zhu Z, Wang L, Bai G, et al. Dexamethasone and vitamin B₁₂synergistically promote peripheral nerve regeneration in rats by upregulating the expression of brain-derived neurotrophic factor. Arch Med Sci. 2012;8:924–30. [DOI] [PubMed] [PMC]

79.

Romano MR, Biagioni F, Carrizzo A, Lorusso M, Spadaro A, Micelli Ferrari T, et al. Effects of vitamin B12 on the corneal nerve regeneration in rats. Exp Eye Res. 2014;120:109–17. [DOI] [PubMed]

80.

Ströhle A, Hahn A. Vitamin C and immune function. Med Monatsschr Pharm. 2009;32:49–54; quiz 55–6. German.

81.

Pohanka M, Pejchal J, Snopkova S, Havlickova K, Karasova JZ, Bostik P, et al. Ascorbic acid: an old player with a broad impact on body physiology including oxidative stress suppression and immunomodulation: a review. Mini Rev Med Chem. 2012;12:35–43. [DOI] [PubMed]

82.

Otten AT, Bourgonje AR, Peters V, Alizadeh BZ, Dijkstra G, Harmsen HJM. Vitamin C supplementation in healthy individuals leads to shifts of bacterial populations in the gut—a pilot study. Antioxidants (Basel). 2021;10:1278. [DOI] [PubMed] [PMC]

83.

Hazan S, Dave S, Papoutsis AJ, Deshpande N, Howell MC Jr, Martin LM. Vitamin C improves gut Bifidobacteria in humans. Future Microbiol. 2022;[Epub ahead of print]. [DOI] [PubMed]

84.

Pham VT, Fehlbaum S, Seifert N, Richard N, Bruins MJ, Sybesma W, et al. Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome– a pilot study. Gut Microbes. 2021;13:e1875774. [DOI] [PubMed] [PMC]

85.

Pham VT, Dold S, Rehman A, Bird JK, Steinert RE. Vitamins, the gut microbiome and gastrointestinal health in humans. Nutr Res. 2021;95:35–53. [DOI] [PubMed]

86.

Karaca I, Palamar M, Guven Yilmaz S, Ates H. Evaluation of ocular surface and Meibomian glands alterations with meibography in patients with inactive Behçet’s uveitis. Curr Eye Res. 2019;44:356–9. [DOI] [PubMed]

87.

Pezzi PP, Paroli MP, Priori R, Da Dalt S, Corradi R. Vogt-Koyanagi-Harada syndrome and keratoconjunctivitis sicca. Am J Ophthalmol. 2004;137:769–70. [DOI] [PubMed]

88.

Brubaker RF, Bourne WM, Bachman LA, McLaren JW. Ascorbic acid content of human corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41:1681–3. [PubMed]

89.

Walsh K. UV radiation and the eye. Optician. 2009;237:26–33.

90.

Cho YW, Yoo WS, Kim SJ, Chung IY, Seo SW, Yoo JM. Efficacy of systemic vitamin C supplementation in reducing corneal opacity resulting from infectious keratitis. Medicine (Baltimore). 2014;93:e125. [DOI] [PubMed] [PMC]

91.

Hayes S, Cafaro TA, Boguslawska PJ, Kamma-Lorger CS, Boote C, Harris J, et al. The effect of vitamin C deficiency and chronic ultraviolet-B exposure on corneal ultrastructure: a preliminary investigation. Mol Vis. 2011;17:3107–15. [PubMed] [PMC]

92.

Cui X, Hong J, Wang F, Deng SX, Yang Y, Zhu X, et al. Assessment of corneal epithelial thickness in dry eye patients. Optom Vis Sci. 2014;91:1446–54. [DOI] [PubMed] [PMC]

93.

Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124:S4–13. [DOI] [PubMed] [PMC]

94.

Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med. 2006;3:349513. [DOI] [PubMed] [PMC]

95.

Cinici E, Cetin N, Ahiskali I, Suleyman B, Altuner D, Alp HH, et al. The effect of thiamine pyrophosphate on ethambutol-induced ocular toxicity. Cutan Ocul Toxicol. 2016;35:222–7. [DOI] [PubMed]

96.

Mathis D, Shoelson SE. Immunometabolism: an emerging frontier. Nat Rev Immunol. 2011;11:81–3. [DOI] [PubMed] [PMC]

97.

Park J, Hosomi K, Kawashima H, Chen YA, Mohsen A, Ohno H, et al. Dietary vitamin B1 intake influences gut microbial community and the consequent production of short-chain fatty acids. Nutrients. 2022;14:2078. [DOI] [PubMed] [PMC]

98.

Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 2018;67:1974–83. [DOI] [PubMed]

99.

Robertson RC, Seira Oriach C, Murphy K, Moloney GM, Cryan JF, Dinan TG, et al. Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in adolescence and adulthood. Brain Behav Immun. 2017;59:21–37. [DOI] [PubMed]

100.

Costantini L, Molinari R, Farinon B, Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci. 2017;18:2645. [DOI] [PubMed] [PMC]

101.

Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21:495–505. [DOI] [PubMed]

102.

Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S–19S. [DOI] [PubMed]

103.

Hussey B, Lindley MR, Mastana SS. Omega 3 fatty acids, inflammation and DNA methylation: an overview. Clin Lipidol. 2017;12:24–32. [DOI]

104.

Cândido FG, Valente FX, Grześkowiak ŁM, Moreira APB, Rocha DMUP, Alfenas RCG. Impact of dietary fat on gut microbiota and low-grade systemic inflammation: mechanisms and clinical implications on obesity. Int J Food Sci Nutr. 2018;69:125–43. [DOI] [PubMed]

105.

Komaroff AL. The microbiome and risk for obesity and diabetes. JAMA. 2017;317:355–6. [DOI] [PubMed]

106.

O’Byrne C, O’Keeffe M. Omega-3 fatty acids in the management of dry eye disease—an updated systematic review and meta-analysis. Acta Ophthalmol. 2023;101:e118–34. [DOI] [PubMed]

107.

Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336–56. [PubMed] [PMC]

108.

Britten-Jones AC, Craig JP, Downie LE. Omega-3 polyunsaturated fatty acids and corneal nerve health: current evidence and future directions. Ocul Surf. 2023;27:1–12. [DOI] [PubMed]

109.

Laird E, Ward M, McSorley E, Strain JJ, Wallace J. Vitamin D and bone health; potential mechanisms. Nutrients. 2010;2:693–724. [DOI] [PubMed] [PMC]

110.

Meyer F, Amaechi BT, Fabritius HO, Enax J. Overview of calcium phosphates used in biomimetic oral care. Open Dent J. 2018;12:406–23. [DOI] [PubMed] [PMC]

111.

Iamartino L, Brandi ML. The calcium-sensing receptor in inflammation: recent updates. Front Physiol. 2022;13:1059369. [DOI] [PubMed] [PMC]

112.

Wang J, Wu S, Zhang Y, Yang J, Hu Z. Gut microbiota and calcium balance. Front Microbiol. 2022;13:1033933. [DOI] [PubMed] [PMC]

113.

He W, Xie Z, Thøgersen R, Rasmussen MK, Zachariassen LF, Jørgensen NR, et al. Effects of calcium source, inulin, and lactose on gut-bone associations in an ovarierectomized rat model. Mol Nutr Food Res. 2022;66:2100883. [DOI] [PubMed] [PMC]

114.

Fuhren J, Schwalbe M, Boekhorst J, Rösch C, Schols HA, Kleerebezem M. Dietary calcium phosphate strongly impacts gut microbiome changes elicited by inulin and galacto-oligosaccharides consumption. Microbiome. 2021;9:218. [DOI] [PubMed] [PMC]

115.

Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. 2015;114:586–95. [DOI] [PubMed]

116.

Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–18. [DOI] [PubMed]

117.

Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26:273–9. [DOI] [PubMed]

118.

Selter JH, Gire AI, Sikder S. The relationship between Graves’ ophthalmopathy and dry eye syndrome. Clin Ophthalmol. 2015;9:57–62. [DOI] [PubMed] [PMC]

119.

Wardenaar F, Brinkmans N, Ceelen I, Van Rooij B, Mensink M, Witkamp R, et al. Micronutrient intakes in 553 Dutch elite and sub-elite athletes: prevalence of low and high intakes in users and non-users of nutritional supplements. Nutrients. 2017;9:142. [DOI] [PubMed] [PMC]

120.

Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2012;16:705–43. [DOI] [PubMed] [PMC]

121.

Bielik V, Kolisek M. Bioaccessibility and bioavailability of minerals in relation to a healthy gut microbiome. Int J Mol Sci. 2021;22:6803. [DOI] [PubMed] [PMC]

122.

Rayman MP. Selenium intake, status, and health: a complex relationship. Hormones (Athens). 2020;19:9–14. [DOI] [PubMed] [PMC]

123.

Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484. [DOI] [PubMed] [PMC]

124.

Ferreira RLU, Sena-Evangelista KCM, de Azevedo EP, Pinheiro FI, Cobucci RN, Pedrosa LFC. Selenium in human health and gut microflora: bioavailability of selenocompounds and relationship with diseases. Front Nutr. 2021;8:685317. [DOI] [PubMed] [PMC]

125.

Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. J Clin Med. 2018;7:258. [DOI] [PubMed] [PMC]

126.

Winther KH, Rayman MP, Bonnema SJ, Hegedüs L. Selenium in thyroid disorders — essential knowledge for clinicians. Nat Rev Endocrinol. 2020;16:165–76. [DOI] [PubMed]

127.

Ismailova DS, Fedorov AA, Grusha YO. Ocular surface changes in thyroid eye disease. Orbit. 2013;32:87–90. [DOI] [PubMed]

128.

Ji X, Dong K, Pu J, Yang J, Zhang Z, Ning X, et al. Comparison of the ocular surface microbiota between thyroid-associated ophthalmopathy patients and healthy subjects. Front Cell Infect Microbiol. 2022;12:914749. [DOI] [PubMed] [PMC]

129.

Mursalin MH, Livingston ET, Callegan MC. The cereus matter of Bacillus endophthalmitis. Exp Eye Res. 2020;193:107959. [DOI] [PubMed] [PMC]

130.

McCullough FS, Northrop-Clewes CA, Thurnham DI. The effect of vitamin A on epithelial integrity. Proc Nutr Soc. 1999;58:289–93. [DOI] [PubMed]

131.

Samarawickrama C, Chew S, Watson S. Retinoic acid and the ocular surface. Surv Ophthalmol. 2015;60:183–95. [DOI] [PubMed]

132.

Chiu M, Dillon A, Watson S. Vitamin A deficiency and xerophthalmia in children of a developed country. J Paediatr Child Health. 2016;52:699–703. [DOI] [PubMed]

133.

Feroze KB, Kaufman EJ. Xerophthalmia. Treasure Island (FL): StatPearls Publishing; 2017.

134.

Liu J, Liu X, Xiong XQ, Yang T, Cui T, Hou NL, et al. Effect of vitamin A supplementation on gut microbiota in children with autism spectrum disorders - a pilot study. BMC Microbiol. 2017;17:204. [DOI] [PubMed] [PMC]

135.

Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4–8. [DOI] [PubMed]

136.

Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95:471–8. [DOI] [PubMed] [PMC]

137.

Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A nested case–control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst. 2007;99:1120–9. [DOI] [PubMed]

138.

Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59:881–6. [DOI] [PubMed] [PMC]

139.

Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010;17:R19–38. [DOI] [PubMed]

140.

Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003;4:269–73. [DOI] [PubMed]

141.

Lagishetty V, Misharin AV, Liu NQ, Lisse TS, Chun RF, Ouyang Y, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010;151:2423–32. [DOI] [PubMed] [PMC]

142.

Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: a systematic review. Nutr Rev. 2018;76:60–76. [DOI] [PubMed]

143.

Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr. 1991;54:548–52. [DOI] [PubMed]

144.

Garcia-Carrasco M, Jiménez-Herrera EA, Gálvez-Romero JL, de Lara LV, Mendoza-Pinto C, Etchegaray-Morales I, et al. Vitamin D and Sjögren syndrome. Autoimmun Rev. 2017;16:587–93. [DOI] [PubMed]

145.

Liu J, Dong Y, Wang Y. Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. Acta Ophthalmol. 2020;98:749–54. [DOI] [PubMed]

146.

Bae SH, Shin YJ, Kim HK, Hyon JY, Wee WR, Park SG. Vitamin D supplementation for patients with dry eye syndrome refractory to conventional treatment. Sci Rep. 2016;6:33083. [DOI] [PubMed] [PMC]

147.

Suwajanakorn O, Puangsricharern V, Kittipibul T, Chatsuwan T. Ocular surface microbiome in diabetes mellitus. Sci Rep. 2022;12:21527. [DOI] [PubMed] [PMC]

148.

Matsha TE, Prince Y, Davids S, Chikte U, Erasmus RT, Kengne AP, et al. Oral microbiome signatures in diabetes mellitus and periodontal disease. J Dent Res. 2020;99:658–65. [DOI] [PubMed]

149.

Thimmappaiah Jagadeesh A, Prakash PY, Karthik Rao N, Ramya V. Culture characterization of the skin microbiome in type 2 diabetes mellitus: a focus on the role of innate immunity. Diabetes Res Clin Pract. 2017;134:1–7. [DOI] [PubMed]

150.

Pang M, Zhu M, Lei X, Chen C, Yao Z, Cheng B. Changes in foot skin microbiome of patients with diabetes mellitus using high-throughput 16S rRNA gene sequencing: a case control study from a single center. Med Sci Monit. 2020;26:e921440. [DOI] [PubMed] [PMC]

151.

Wang G, Hu YX, He MY, Xie YH, Su W, Long D, et al. Gut-lung dysbiosis accompanied by diabetes mellitus leads to pulmonary fibrotic change through the NF-κB signaling pathway. Am J Pathol. 2021;191:838–56. [DOI] [PubMed]

152.

Cheng C, Wang Z, Wang J, Ding C, Sun C, Liu P, et al. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl Lung Cancer Res. 2020;9:693–704. [DOI] [PubMed] [PMC]

153.

Barlow GM, Yu A, Mathur R. Role of the gut microbiome in obesity and diabetes mellitus. Nutr Clin Pract. 2015;30:787–97. [DOI] [PubMed]

154.

Shih KC, Lam KS, Tong L. A systematic review on the impact of diabetes mellitus on the ocular surface. Nutr Diabetes. 2017;7:e251. [DOI] [PubMed] [PMC]

155.

Zhang X, Zhao L, Deng S, Sun X, Wang N. Dry eye syndrome in patients with diabetes mellitus: prevalence, etiology, and clinical characteristics. J Ophthalmol. 2016;2016:8201053. [DOI] [PubMed] [PMC]

156.

Seifart U, Strempel I. The dry eye and diabetes mellitus. Ophthalmologe. 1994;91:235–9. German. [PubMed]

157.

Martins EN, Alvarenga LS, Höfling-Lima AL, Freitas D, Zorat-Yu MC, Farah ME, et al. Aerobic bacterial conjunctival flora in diabetic patients. Cornea. 2004;23:136–42. [DOI] [PubMed]

158.

Fernández-Rubio ME, Rebolledo-Lara L, Martinez-García M, Alarcón-Tomás M, Cortés-Valdés C. The conjunctival bacterial pattern of diabetics undergoing cataract surgery. Eye (Lond). 2010;24:825–34. [DOI] [PubMed]

159.

Karimsab D, Razak SK. Study of aerobic bacterial conjunctival flora in patients with diabetes mellitus. Nepal J Ophthalmol. 2013;5:28–32. [DOI] [PubMed]

160.

Bilen H, Ates O, Astam N, Uslu H, Akcay G, Baykal O. Conjunctival flora in patients with type 1 or type 2 diabetes mellitus. Adv Ther. 2007;24:1028–35. [DOI] [PubMed]

161.

Ham B, Hwang HB, Jung SH, Chang S, Kang KD, Kwon MJ. Distribution and diversity of ocular microbial communities in diabetic patients compared with healthy subjects. Curr Eye Res. 2018;43:314–24. [DOI] [PubMed]

162.

Li S, Yi G, Peng H, Li Z, Chen S, Zhong H, et al. How ocular surface microbiota debuts in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2019;9:202. [DOI] [PubMed] [PMC]

163.

Zhu X, Wei L, Rong X, Zhang Y, Zhang Q, Wen X, et al. Conjunctival microbiota in patients with type 2 diabetes mellitus and influences of perioperative use of topical levofloxacin in ocular surgery. Front Med (Lausanne). 2021;8:605639. [DOI] [PubMed] [PMC]

164.

Rahmani S, Eliott D. Postoperative endophthalmitis: a review of risk factors, prophylaxis, incidence, microbiology, treatment, and outcomes. Semin Ophthalmol. 2018;33:95–101. [DOI] [PubMed]

165.

Rajarajan M, Madduri B, Mohan N, Fernandes M. Enterobacter cloacae keratitis: clinicomicrobiological profiles, risk factors, and outcomes. Cornea. 2022;41:1110–15. [DOI] [PubMed]

166.

Pathengay A, Trehan HS, Mathai A, Jalali S, Majji AB, Das MK, et al. Enterobacter endophthalmitis: clinicomicrobiologic profile and outcomes. Retina. 2012;32:558–62. [DOI] [PubMed]

167.

Som S, Basu S, Mukherjee D, Deb S, Choudhury PR, Mukherjee S, et al. Ascorbic acid metabolism in diabetes mellitus. Metabolism. 1981;30:572–7. [DOI] [PubMed]

168.

Santosh HN, David CM. Role of ascorbic acid in diabetes mellitus: a comprehensive review. J Med Radiol Pathol Surg. 2017;4:1–3. [DOI]

169.

Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev. 1996;54:193–202. [DOI] [PubMed]

170.

Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71–82. [DOI] [PubMed] [PMC]

171.

Khoo P, Ooi KG, Watson S. Effectiveness of pharmaceutical interventions for meibomian gland dysfunction: an evidence-based review of clinical trials. Clin Exp Ophthalmol. 2019;47:658–68. [DOI] [PubMed]

172.

Najjaran M, Zarei-Ghanavati S, Arjmand Askari E, Eslampoor A, Ziaei M. Effect of oral vitamin D supplementation on dry eye disease patients with vitamin D deficiency. Clin Exp Optom. 2023;106:257–62. [DOI] [PubMed]

173.

Askari G, Rafie N, Miraghajani M, Heidari Z, Arab A. Association between vitamin D and dry eye disease: a systematic review and meta-analysis of observational studies. Cont Lens Anterior Eye. 2020;43:418–25. [DOI] [PubMed]

174.

Ren X, Chou Y, Jiang X, Hao R, Wang Y, Chen Y, et al. Effects of oral vitamin B1 and mecobalamin on dry eye disease. J Ophthalmol. 2020;2020:9539674. [DOI] [PubMed] [PMC]

175.

Alanazi SA, El-Hiti GA, Al-Baloud AA, Alfarhan MI, Al-Shahrani A, Albakri AA, et al. Effects of short-term oral vitamin A supplementation on the ocular tear film in patients with dry eye. Clin Ophthalmol. 2019;13:599–604. [DOI] [PubMed] [PMC]

176.

Huang JY, Yeh PT, Hou YC. A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. Clin Ophthalmol. 2016;10:813–20. [DOI] [PubMed] [PMC]

177.

Ajith TA. Alpha-lipoic acid: a possible pharmacological agent for treating dry eye disease and retinopathy in diabetes. Clin Exp Pharmacol Physiol. 2020;47:1883–90. [DOI] [PubMed]

178.

Wu Y, Wu J, Bu J, Tang L, Yang Y, Ouyang W, et al. High-fat diet induces dry eye-like ocular surface damages in murine. Ocul Surf. 2020;18:267–76. [DOI] [PubMed]

179.

Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J. Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies. Clin Ophthalmol. 2020;14:119–26. [DOI] [PubMed] [PMC]

180.

Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016;123:425–33. [DOI] [PubMed] [PMC]

181.

Watson S. Meibomian gland disease and the microbiotome: Is it time for ocular probiotics? Clin Exp Ophthalmol. 2017;45:103–4. [DOI] [PubMed]

182.

Watane A, Cavuoto KM, Rojas M, Dermer H, Day JO, Banerjee S, et al. Fecal microbial transplant in individuals with immune-mediated dry eye. Am J Ophthalmol. 2022;233:90–100. [DOI] [PubMed] [PMC]

183.

Mahajan R, Midha V, Singh A, Mehta V, Gupta Y, Kaur K, et al. Incidental benefits after fecal microbiota transplant for ulcerative colitis. Intest Res. 2020;18:337–40. [DOI] [PubMed] [PMC]

184.

Bielory L. Allergic conjunctivitis and the impact of allergic rhinitis. Curr Allergy Asthma Rep. 2010;10:122–34. [DOI] [PubMed]